David Li, Justin Weinkauf, Alim Hirji, Jason Weatherald, Rhea Varughese, Laura van den Bosch, Dale Lien, Jayan Nagendran, Kieran Halloran
{"title":"Lung Transplantation From Donors With a History of Substance Use","authors":"David Li, Justin Weinkauf, Alim Hirji, Jason Weatherald, Rhea Varughese, Laura van den Bosch, Dale Lien, Jayan Nagendran, Kieran Halloran","doi":"10.1111/ctr.70162","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Substance use is common among lung transplant donors, but concerns persist about graft damage. Stimulant drugs such as cocaine and methamphetamine can induce pulmonary arterial hypertension, while smoked products such as cannabis and crack cocaine can produce airway and parenchymal diseases. We sought to characterize donor substance use at our center and evaluate the associations with recipient survival as well as chronic lung allograft dysfunction (CLAD), severe primary graft dysfunction (PGD3), and baseline lung allograft dysfunction (BLAD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We studied patients with double lung transplants in our program between 2004 and 2016, including a history of donor substance use with nine pre-specified agents. We modeled the association with time to death or retransplant, CLAD, severe PGD, and BLAD.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 473 recipients, 186 (39%) received lungs from a donor with a history of substance use with at least one of the pre-specified substances. There was no overall relationship between donor substance use and any outcome. Heavy donor smoking was associated with an increased risk of death or retransplant (hazard ratio 1.47; <i>p</i> = 0.032), PGD3 (odds ratio [OR]: 2.13; <i>p</i> = 0.014), and BLAD (OR 2.56; <i>p</i> < 0.001). Donor crack cocaine use (<i>n</i> = 24) was also associated with worse survival (HR 2.16; 95% CI 1.16–3.66; <i>p</i> = 0.017) but not CLAD or BLAD. We noted no CLAD associations with any drug.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>A history of donor substance use was common and in general not associated with worse outcomes, aside from heavy donor smoking. These findings may have implications for allocation and post-transplant graft dysfunction.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 5","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70162","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70162","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Substance use is common among lung transplant donors, but concerns persist about graft damage. Stimulant drugs such as cocaine and methamphetamine can induce pulmonary arterial hypertension, while smoked products such as cannabis and crack cocaine can produce airway and parenchymal diseases. We sought to characterize donor substance use at our center and evaluate the associations with recipient survival as well as chronic lung allograft dysfunction (CLAD), severe primary graft dysfunction (PGD3), and baseline lung allograft dysfunction (BLAD).
Methods
We studied patients with double lung transplants in our program between 2004 and 2016, including a history of donor substance use with nine pre-specified agents. We modeled the association with time to death or retransplant, CLAD, severe PGD, and BLAD.
Results
Of 473 recipients, 186 (39%) received lungs from a donor with a history of substance use with at least one of the pre-specified substances. There was no overall relationship between donor substance use and any outcome. Heavy donor smoking was associated with an increased risk of death or retransplant (hazard ratio 1.47; p = 0.032), PGD3 (odds ratio [OR]: 2.13; p = 0.014), and BLAD (OR 2.56; p < 0.001). Donor crack cocaine use (n = 24) was also associated with worse survival (HR 2.16; 95% CI 1.16–3.66; p = 0.017) but not CLAD or BLAD. We noted no CLAD associations with any drug.
Conclusion
A history of donor substance use was common and in general not associated with worse outcomes, aside from heavy donor smoking. These findings may have implications for allocation and post-transplant graft dysfunction.
期刊介绍:
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.